Quarterly results

Search for previous results

Latest results

2016 Fourth Quarter

Watch Sir Andrew Witty, CEO, and Simon Dingemans, CFO discuss our full year 2016 results. Watch Patrick Vallance, President, Pharmaceuticals R&D, also give an update on R&D.

Listen to the webcast

Watch Simon Dingemans, CFO, discussing GSK’s fourth quarter results 2016

Full year highlights

  • +6%*

    GSK Group sales

  • +12%*

    Core EPS

  • £1.4bn

    Cost savings

  • +3%*

    Pharma sales growth

  • +14%*

    Vaccines sales growth

  • +9%*

    Consumer Healthcare sales growth

  • 20-30

    Potential assets with key data expected by end of 2018

  • *

    Q3 growth rates at Constant Exchange Rates (CER)

Back to top